OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Multilayered Research Framework for Humanities and Epidemiology of Medicinal Product Risk Communication
Priya Bahri
Springer eBooks (2020), pp. 1-84
Closed Access | Times Cited: 8
Priya Bahri
Springer eBooks (2020), pp. 1-84
Closed Access | Times Cited: 8
Showing 8 citing articles:
Review of studies evaluating the effectiveness of risk minimization measures for oncology medicinal products registered in the european medicines agency (HMA-EMA) catalogue: findings and lessons learned
Jorge Monteiro, Diogo Fraxino de Almeida, João Paulo Fernandes, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Jorge Monteiro, Diogo Fraxino de Almeida, João Paulo Fernandes, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
The ISoP PatEG-SIG for Promoting Patient Engagement in Pharmacovigilance: A Change of Paradigm is Needed
Manal M. Younus, Mayada Alkhakany, Priya Bahri, et al.
Drug Safety (2023) Vol. 46, Iss. 7, pp. 619-623
Open Access | Times Cited: 8
Manal M. Younus, Mayada Alkhakany, Priya Bahri, et al.
Drug Safety (2023) Vol. 46, Iss. 7, pp. 619-623
Open Access | Times Cited: 8
The STAR Compass to Guide Future Pharmacovigilance Based on a 10-Year Review of the Strengthened EU System
Priya Bahri, Georgy Genov, Peter Arlett, et al.
Drug Safety (2024) Vol. 47, Iss. 10, pp. 941-956
Open Access | Times Cited: 2
Priya Bahri, Georgy Genov, Peter Arlett, et al.
Drug Safety (2024) Vol. 47, Iss. 10, pp. 941-956
Open Access | Times Cited: 2
Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET)
Priya Bahri, Daniel R. Morales, Adrien Inoubli, et al.
Drug Safety (2020) Vol. 44, Iss. 2, pp. 193-209
Open Access | Times Cited: 15
Priya Bahri, Daniel R. Morales, Adrien Inoubli, et al.
Drug Safety (2020) Vol. 44, Iss. 2, pp. 193-209
Open Access | Times Cited: 15
Systematising Pharmacovigilance Engagement of Patients, Healthcare Professionals and Regulators: A Practical Decision Guide Derived from the International Risk Governance Framework for Engagement Events and Discourse
Priya Bahri, Alexandre Pariente
Drug Safety (2021) Vol. 44, Iss. 11, pp. 1193-1208
Open Access | Times Cited: 11
Priya Bahri, Alexandre Pariente
Drug Safety (2021) Vol. 44, Iss. 11, pp. 1193-1208
Open Access | Times Cited: 11
A quantitative investigation in a territory of Italy on citizens’ attitudes towards medicines through the COVID-19 pandemic: the importance of possible indirect effects caused by the pandemic
Antonio Mastino, Francesca Pettinau, Piergiorgio Palla, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access
Antonio Mastino, Francesca Pettinau, Piergiorgio Palla, et al.
Journal of Pharmaceutical Policy and Practice (2024) Vol. 17, Iss. 1
Open Access
Pioglitazone use in Australia and the United Kingdom following drug safety advisories on bladder cancer risk: An interrupted time series study
Anna Kemp, Barbara Mintzes, Richard L. Morrow, et al.
Pharmacoepidemiology and Drug Safety (2022) Vol. 31, Iss. 10, pp. 1039-1045
Open Access | Times Cited: 2
Anna Kemp, Barbara Mintzes, Richard L. Morrow, et al.
Pharmacoepidemiology and Drug Safety (2022) Vol. 31, Iss. 10, pp. 1039-1045
Open Access | Times Cited: 2
The Unintended Consequences of Adverse Event Information on Medicines’ Risks and Label Content
Giovanni Furlan, David V. Power
Pharmaceutical Medicine (2020) Vol. 34, Iss. 6, pp. 369-380
Closed Access | Times Cited: 1
Giovanni Furlan, David V. Power
Pharmaceutical Medicine (2020) Vol. 34, Iss. 6, pp. 369-380
Closed Access | Times Cited: 1
